Arixtra

Deep Vein Thrombosis, Angina, Unstable, Hip structure + 7 more

Treatment

20 Active Studies for Arixtra

What is Arixtra

Fondaparinux

The Generic name of this drug

Treatment Summary

Fondaparinux (Arixtra) is a man-made anticoagulant that helps prevent the formation of blood clots. It is similar to heparin and heparan sulfate, which contain small molecules that bind to antithrombin III, an enzyme that helps stop blood clots from forming. Fondaparinux binds even more tightly to antithrombin III and is 300 times more effective in stopping blood clots from forming. It is used to prevent blood clots after orthopedic surgery, abdominal surgery, and for the treatment of deep vein thrombosis, pulmonary emb

Arixtra

is the brand name

image of different drug pills on a surface

Arixtra Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Arixtra

Fondaparinux

2001

46

Effectiveness

How Arixtra Affects Patients

Fondaparinux works by increasing the activity of the body's natural anticoagulant (ATIII) which helps to stop the formation of blood clots. It has no known effect on platelet function, and it does not affect fibrinolytic activity or bleeding time. Generally, monitoring of fondaparinux is not needed, but it may be recommended for those with kidney problems or pregnant women. It is important to keep track of kidney function and complete blood count (CBC) during treatment. There is currently no antidote for fondaparinux.

How Arixtra works in the body

Fondaparinux is an anticoagulant drug that stops the formation of blood clots by preventing Factor Xa from working. Factor Xa is an important part of the blood clotting process, so by blocking it, fondaparinux interrupts the clotting process and prevents thrombus formation. Fondaparinux does not usually cause the same side effects as other anticoagulants, such as heparin-induced thrombocytopenia, but rare cases have been reported.

When to interrupt dosage

The endorsed measure of Arixtra is contingent upon the identified condition, including Unstable Angina Pectoris, Deep Vein Thrombosis and Deep Vein Thrombosis. The measure of dosage fluctuates, as per the procedure of delivery (e.g. Solution - Intravenous; Subcutaneous or Subcutaneous) outlined in the subsequent table.

Condition

Dosage

Administration

acute, superficial, symptomatic Vein Thrombosis

, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL

, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Solution - Intravenous; Subcutaneous, Solution, Intravenous; Subcutaneous, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection - Subcutaneous, Injection

Hip structure

, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL

, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Solution - Intravenous; Subcutaneous, Solution, Intravenous; Subcutaneous, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection - Subcutaneous, Injection

Heart Attack

, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL

, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Solution - Intravenous; Subcutaneous, Solution, Intravenous; Subcutaneous, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection - Subcutaneous, Injection

Abdominal Surgeries

, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL

, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Solution - Intravenous; Subcutaneous, Solution, Intravenous; Subcutaneous, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection - Subcutaneous, Injection

Fracture

, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL

, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Solution - Intravenous; Subcutaneous, Solution, Intravenous; Subcutaneous, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection - Subcutaneous, Injection

Total Knee Arthroplasty

, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL

, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Solution - Intravenous; Subcutaneous, Solution, Intravenous; Subcutaneous, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection - Subcutaneous, Injection

Myocardial Infarction

, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL

, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Solution - Intravenous; Subcutaneous, Solution, Intravenous; Subcutaneous, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection - Subcutaneous, Injection

Pulmonary Embolism

, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL

, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Solution - Intravenous; Subcutaneous, Solution, Intravenous; Subcutaneous, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection - Subcutaneous, Injection

Angina, Unstable

, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL

, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Solution - Intravenous; Subcutaneous, Solution, Intravenous; Subcutaneous, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection - Subcutaneous, Injection

Deep Vein Thrombosis

, 50.0 mg/mL, 25.0 mg/mL, 75.0 mg/mL, 100.0 mg/mL, 15.0 mg/mL

, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Solution - Intravenous; Subcutaneous, Solution, Intravenous; Subcutaneous, Solution - Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection - Subcutaneous, Injection

Warnings

Arixtra Contraindications

Condition

Risk Level

Notes

Thinness

Do Not Combine

Endocarditis, Bacterial

Do Not Combine

Low Platelet Count

Do Not Combine

Hemorrhage

Do Not Combine

There are 20 known major drug interactions with Arixtra.

Common Arixtra Drug Interactions

Drug Name

Risk Level

Description

Albutrepenonacog alfa

Major

The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Fondaparinux.

Andexanet alfa

Major

The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Fondaparinux.

Anti-inhibitor coagulant complex

Major

The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Fondaparinux.

Antihemophilic factor (recombinant), PEGylated

Major

The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Fondaparinux.

Antihemophilic factor human

Major

The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Fondaparinux.

Arixtra Toxicity & Overdose Risk

Taking anticoagulants can increase the risk of bleeding. This risk may be amplified in those with kidney or liver issues, or in people who weigh less than 50kg.

image of a doctor in a lab doing drug, clinical research

Arixtra Novel Uses: Which Conditions Have a Clinical Trial Featuring Arixtra?

54 active trials are currently being conducted to assess the potential of Arixtra to treat Total Knee Replacement, Unstable Angina Pectoris and Deep Vein Thrombosis.

Condition

Clinical Trials

Trial Phases

acute, superficial, symptomatic Vein Thrombosis

0 Actively Recruiting

Fracture

1 Actively Recruiting

Not Applicable

Hip structure

0 Actively Recruiting

Heart Attack

5 Actively Recruiting

Phase 2, Not Applicable, Phase 3, Phase 1

Pulmonary Embolism

4 Actively Recruiting

Not Applicable, Phase 2

Deep Vein Thrombosis

9 Actively Recruiting

Not Applicable, Phase 2, Phase 3, Phase 4

Abdominal Surgeries

1 Actively Recruiting

Not Applicable

Total Knee Arthroplasty

6 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Myocardial Infarction

2 Actively Recruiting

Not Applicable, Phase 3

Angina, Unstable

2 Actively Recruiting

Not Applicable

Arixtra Reviews: What are patients saying about Arixtra?

5

Patient Review

6/26/2011

Arixtra for Deep Vein Thrombosis Prevention in Knee Replacement

I was diagnosed with portal vein thrombosis in 2002 and placed on coumadin. During the next two years, I had reoccurring lung clots in my upper and lower lobes. Lovenox and Arixtra have been a miracle drug for me; I haven't had any clots in four years. This will be a life-time drug for me also. My condition today is fair with much fatigue. I also have Budd-Chiari syndrome, which Arixtra is helping with the inflow and outflow of liver blood. I am blessed to be given a longer life with my family--

5

Patient Review

7/13/2011

Arixtra for Deep Vein Thrombosis Prevention in Knee Replacement

I really appreciate how easy it is to use this self-dosing needle. They retract into the cartridge so you don't have to worry about disposing of them, and if you follow the directions they cause very little pain. I also haven't had any side effects, which is amazing because I'm sensitive to a lot of medications. And it's great that my health insurance covers such a large percentage of the cost!

5

Patient Review

9/18/2015

Arixtra for Acute Blood Clot in a Blood Vessel Supplying the Lungs

I couldn't tolerate the other options, but this one really works well for me. The only downside is that you have to pinch your skin while administering the shot, but it's worth it to avoid bruising.

5

Patient Review

2/20/2019

Arixtra for Deep Vein Thrombosis Prevention

Coumadin and other therapies failed me, so I had to switch to Arixtra. It's been eight years with no side effects. This medication is expensive, but it saved my life.

4.7

Patient Review

1/19/2011

Arixtra for Blood Clots in Deep Veins and in Blood Vessel of the Lung

I have antiphosolipid antibody syndrome and have been on warfarin for 3yrs. A recent misdiagnosis of a blood clot has now left me with no choice but heparin for life. I have found the cost of arixtra to be exhorbitant compared to warfarin and the bruising and hematomas are awful, though not as bad as lovenox.

4.3

Patient Review

9/12/2010

Arixtra for Deep Vein Thrombosis Prevention

I have been on Arixtra injections for 10 months, as per my doctor's recommendation, and I am wondering about the long-term effects of this medication. From what I can tell, there are a range of potential side effects associated with its use. Has anyone else experienced any problems?

4.3

Patient Review

8/17/2010

Arixtra for Acute Blood Clot in a Blood Vessel Supplying the Lungs

3.7

Patient Review

1/21/2013

Arixtra for Treatment to Prevent a Blood Clot in the Lung

I would prefer an pill or something over having to take a daily shot, but this treatment is still helpful. I'm only 19 and will have to take it for the rest of my life though, so hopefully they come out with an easier way to administer it soon.

2.3

Patient Review

4/14/2012

Arixtra for Blood Clot in a Deep Vein

This is extremely difficult to administer, even for professionals. The consumer information is very lacking, and it's so new that pharmacists and doctors are not familiar with it. I can't find any long term clinical studies on this either.

1.7

Patient Review

10/4/2012

Arixtra for Deep Vein Thrombosis Prevention in Hip Surgery

This treatment caused me to develop a rash on my upper arms and chest, as well as bruising and bleeding from my wound. Overall, I was not pleased with the results.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about arixtra

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of drug is Arixtra?

"Arixtra belongs to a class of drugs called factor Xa (ten A) inhibitors, which work by reducing the ability of blood to clot."

Answered by AI

What is the drug Arixtra used for?

"Fondaparinux is a medication that is used to treat serious blood clots. It is usually used in conjunction with another medication called warfarin. If blood clots are not treated, they can travel to the lungs, heart, or brain and cause serious problems such as a heart attack or stroke."

Answered by AI

Is Arixtra the same as Lovenox?

"Arixtra is used to prevent and treat DVT and pulmonary embolism (blood clots in the lungs).

Are Arixtra and Lovenox the same thing? No, they are not. Lovenox is a blood thinner (anticoagulant) used to prevent blood clots. Arixtra is also a blood thinner used to prevent and treat DVT and pulmonary embolism (blood clots in the lungs)."

Answered by AI

Is Arixtra a heparin product?

"Arixtra (fondaparinux) is not a type of heparin. It is an anticoagulant that prevents and treats blood clots, but it works in a different way. It can be a good option for people who are allergic to heparin products."

Answered by AI

Clinical Trials for Arixtra

Image of Tampa General Hospital in Tampa, United States.

Fasting for Myocardial Infarction

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to find out whether fasting is necessary before urgent inpatient cardiac catheterizations. For patients presenting with urgent heart-related pain or even mild heart attacks, researchers want to know whether eating and drinking before their procedure improves comfort without raising the risk of complications. The study will answer: * Does eating and drinking before the procedure improve patient comfort? * Does it increase the risk of adverse events like vomiting, aspiration (food or liquid entering the lungs), breathing problems, or death, etc? Participants will be randomly assigned to either: * A standard fasting group (no food for 6 hours, no clear liquids for 2 hours), or * A no-fasting group (able to eat and drink as usual). Patients will complete brief surveys before the procedure to assess comfort and satisfaction. Researchers will also review medical records weekly and 30 days later to monitor for safety outcomes.

Recruiting
Has No Placebo

Tampa General Hospital

Samip Vasaiwala, MD

Have you considered Arixtra clinical trials?

We made a collection of clinical trials featuring Arixtra, we think they might fit your search criteria.
Go to Trials
Image of UPMC Horizon in Pittsburgh, United States.

Pip Care Platform for Abdominal Surgery

18+
All Sexes
Pittsburgh, PA

Pip Care is developing a personalized, interactive surgical journey platform with a live health coach that works directly with health systems to optimize the perioperative care process. Our Health Insurance Portability and Accountability Act (HIPAA)-compliant platform, Pip, can be integrated into any electronic medical record (EMR), thus alleviating the administrative burden by making operational workflows more efficient. The PIP empowers patients and their families to be more involved in their care by breaking down a patient's healthcare plan into definable, easy-to-understand, and easy-to-complete tasks. Additionally, a health coach completes a health intake to create a personalized perioperative care plan, meets regularly with the patient to encourage goal accomplishment, and facilitates care coordination. This project has 2 phases; Phase I is to assess usability of the Pip Care platform in surgical patients, Phase II is a RCT (Randomized Controlled Trial) to assess surgical clinical outcomes while using Pip compared to standard of care.

Recruiting
Has No Placebo

UPMC Horizon (+7 Sites)

Jennifer Holder-Murray, MD

Image of RUSH University Medical Center in Chicago, United States.

Thrombolysis/Thrombectomy for Deep Vein Thrombosis

18 - 75
All Sexes
Chicago, IL

The goal of this study is to fill the paucity of second line endovascular treatment for acute deep venous thrombus (DVT) by using catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) as adjunctive second-line treatments for acute DVT patients who show no improvement after an initial anticoagulation trial for one week. The main questions the study aims to answer are: \- Are adjunctive use of endovascular interventional treatments as second-line to DVT treatment safe and efficient? Participants will be followed with repeat US at 1 week after initial DVT to assess for response to anticoagulation treatment. If there is significant residual thrombus with minimal or no response to treatment, participants will be offered enrollment to the study in the office or inpatient setting. Enrolled participants will be randomized into control or intervention arms with 1:1 ratio. Researchers will compare follow-up Villalta and Marder scores between groups to see whether endovascular interventions are safe and efficient.

Phase 4
Waitlist Available

RUSH University Medical Center

Bulent Arslan, MD

Have you considered Arixtra clinical trials?

We made a collection of clinical trials featuring Arixtra, we think they might fit your search criteria.
Go to Trials

Have you considered Arixtra clinical trials?

We made a collection of clinical trials featuring Arixtra, we think they might fit your search criteria.
Go to Trials